Clinical Trial Update: Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma [NA]

View source ↗

Summary

This clinical trial update describes a study evaluating low-dose bevacizumab and atezolizumab in combination with TACE-HAIC for unresectable hepatocellular carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab | NA | Status: NOT_YET_RECRUITING